AbbVie (ABBV) has announced that Canada's Drug Agency has recommended the reimbursement of VRAYLAR, subject to certain conditions, for the treatment of schizophrenia in adults. VRAYLAR, an atypical antipsychotic medication, received its Notice of Compliance from Health Canada in 2022.
"This significant milestone for VRAYLAR underscores AbbVie's dedication to not only introducing new therapeutic options for severe mental illnesses in Canada but also collaborating with governments, clinicians, and community stakeholders to eliminate disparities and ensure these medications are accessible to all Canadian patients," stated Rami Fayed, Vice President and General Manager, AbbVie Canada.
